High Prevalence of Headaches During Covid‐19 Infection: A Retrospective Cohort Study.

Saved in:
Bibliographic Details
Title: High Prevalence of Headaches During Covid‐19 Infection: A Retrospective Cohort Study.
Authors: Poncet‐Megemont, Louis, Paris, Pauline, Tronchere, Amélie, Salazard, Jean‐Pascal, Pereira, Bruno, Dallel, Radhouane, Aumeran, Claire, Beytout, Jean, Jacomet, Christine, Laurichesse, Henri, Lesens, Olivier, Mrozek, Natacha, Vidal, Magali, Moisset, Xavier
Source: Headache: The Journal of Head & Face Pain. Nov2020, Vol. 60 Issue 10, p2578-2582. 5p.
Subjects: Academic medical centers, Ageusia, Chest X rays, Computed tomography, Confidence intervals, Convalescence, Coronavirus diseases, Dyspnea, Fever, Headache, Interviewing, Longitudinal method, Research methodology, Smell disorders, Retrospective studies, COVID-19, Symptoms
Geographic Terms: France
Abstract: Objectives: To document the prevalence of new headaches in patients with Covid‐19 infection and the potential association with other neuro‐sensorial symptoms (anosmia and ageusia). The persistence of these symptoms 1 month after recovery was also documented. Background: Headaches are a very common symptom of viral infections. Surprisingly, early Chinese studies reported a relatively low prevalence (12‐15%) of headaches associated with Covid‐19. Methods: All the patients with laboratory‐confirmed or chest‐CT‐confirmed Covid‐19 infection, diagnosed between February 27th and April 15th, 2020 in the dedicated laboratory of Clermont‐Ferrand University Hospital were followed for 1 month after recovery. Results: A total of 139 consecutive patients (mean [SD] age, 48.5 [15.3] years; 87 women [62.6%]) were interviewed 1 month after disappearance of fever and dyspnea (semi‐structured phone interview). Overall, 59.0% (82/139) of people with Covid‐19 had mild disease, 36.7% (51/139) had severe disease, and 4.3% (6/139) had critical illness. Eighty‐two (59.0%; 95% CI: 50.3 to 67.3) reported new headaches during the acute phase and 3.6% (5/139) had persistent headaches 1 month after fever and dyspnea remission. Anosmia and ageusia were also very common, occurring in 60.4% (84/139) and 58.3% (81/139) of the patients, respectively. These 2 symptoms persisted in 14.4% (20/139) and 11.5% (16/139) of Covid‐19 patients 1 month after recovery. Headaches were neither clearly associated with anosmia, nor with ageusia, and were not associated with disease severity (ie, requiring hospitalization or intensive care unit). Conclusion: This specific study highlights the high prevalence of new headaches during Covid‐19 infection in French patients. Further studies are needed to refine the characterization of patients with Covid‐19‐associated headaches. [ABSTRACT FROM AUTHOR]
Copyright of Headache: The Journal of Head & Face Pain is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
Description
Abstract:Objectives: To document the prevalence of new headaches in patients with Covid‐19 infection and the potential association with other neuro‐sensorial symptoms (anosmia and ageusia). The persistence of these symptoms 1 month after recovery was also documented. Background: Headaches are a very common symptom of viral infections. Surprisingly, early Chinese studies reported a relatively low prevalence (12‐15%) of headaches associated with Covid‐19. Methods: All the patients with laboratory‐confirmed or chest‐CT‐confirmed Covid‐19 infection, diagnosed between February 27th and April 15th, 2020 in the dedicated laboratory of Clermont‐Ferrand University Hospital were followed for 1 month after recovery. Results: A total of 139 consecutive patients (mean [SD] age, 48.5 [15.3] years; 87 women [62.6%]) were interviewed 1 month after disappearance of fever and dyspnea (semi‐structured phone interview). Overall, 59.0% (82/139) of people with Covid‐19 had mild disease, 36.7% (51/139) had severe disease, and 4.3% (6/139) had critical illness. Eighty‐two (59.0%; 95% CI: 50.3 to 67.3) reported new headaches during the acute phase and 3.6% (5/139) had persistent headaches 1 month after fever and dyspnea remission. Anosmia and ageusia were also very common, occurring in 60.4% (84/139) and 58.3% (81/139) of the patients, respectively. These 2 symptoms persisted in 14.4% (20/139) and 11.5% (16/139) of Covid‐19 patients 1 month after recovery. Headaches were neither clearly associated with anosmia, nor with ageusia, and were not associated with disease severity (ie, requiring hospitalization or intensive care unit). Conclusion: This specific study highlights the high prevalence of new headaches during Covid‐19 infection in French patients. Further studies are needed to refine the characterization of patients with Covid‐19‐associated headaches. [ABSTRACT FROM AUTHOR]
ISSN:00178748
DOI:10.1111/head.13923